Therefore, we investigated whether MA, a proven natural inhibitor of PLA2, could inhibit KRAS-mutated lung cancer cells to find a new therapeutic approach for EGFR-TKI-resistant lung cancer cells. This evidence concerns the gene KRAS and lung cancer.